Market Overview

UPDATE: Piper Jaffray Upgrades Medidata Solutions to Overweight on Revenue Growth

Related MDSO
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
Medidata Solutions (MDSO) Set to Join the S&P 400 Index

Piper Jaffray raised its rating on Medidata Solutions (NASDAQ: MDSO) from Neutral to Overweight and increased its target price from $31 to $54.

Piper Jaffray commented, "We've always viewed the cloud as a better model for health care, but initially we failed to see the implications for the clinical trials market. We get it now. And because Medidata has the only cloud-based EDC application on the market, we believe the current sales momentum is sustainable. Growing at this rate is no easy task, it will take added investments to support an accelerating top line growth rate. We're fine with that. This is a SaaS model that we believe will grow 20% top line next year with a 99% retention rate, and huge opportunities to cross-sell and grow market share."

Medidata Solutions closed at $42.02 on Wednesday.

Latest Ratings for MDSO

Nov 2017DoughertyUpgradesNeutralBuy
Oct 2017Wells FargoMaintainsMarket Perform
Sep 2017RBC CapitalInitiates Coverage OnSector Perform

View More Analyst Ratings for MDSO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (MDSO)

View Comments and Join the Discussion!

Partner Center